BioVentures has announced a licensing agreement with Harmonic Discovery and UC San Francisco for the development of a new drug, HD-10019, targeting FLT3-mutated acute myeloid leukemia (AML). This innovative compound, emerging from a collaboration between the University of Arkansas for Medical Sciences and UCSF, represents a significant advancement in AML treatment. 

HD-10019, designed as a type II kinase inhibitor, aims to address the limitations of current AML therapies. Its development focuses on improving treatment efficacy and reducing side effects, such as myelosuppression, which are commonly associated with existing AML treatments. 

This partnership underscores BioVentures’ dedication to pioneering healthcare solutions. By collaborating with Harmonic Discovery’s precision pharmacology platform, BioVentures is at the forefront of introducing groundbreaking treatments in the fight against challenging diseases like AML. 

Read more about this story here.